2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

1. McCluggage WG, Sumathi VP, Maxwell P. CD10 is a sensitive and
diagnostically useful immunohistochemical marker of normal endometrial
stroma and of endometrial stromal neoplasms. Histopathology. 2001;39:273-278.
2. Nucci MR, O’Connell JT, Huettner PC, et al. h-Caldesmon expression
effectively distinguishes endometrial stromal tumors from uterine smooth
muscle tumors. Am J Surg Pathol. 2001;25:455-463.
3. Koontz JI, Soreng AL, Nucci M, et al. Frequent fusion of the JAZF1 and
JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci U S A.
2001;98:6348-6353.
4. Micci F, Walter CU, Teixeira MR, Panagopoulos I, Bjerkehagen B,
Saeter G, Heim S. Cytogenetic and molecular genetic analyses of endometrial
stromal sarcoma: nonrandom involvement of chromosome arms 6p and 7p and
confirmation of JAZF1/JJAZ1 gene fusion in t(7;17). Cancer Genet Cytogenet.
2003;144:119-124.
5. Bodner K, Bodner-Adler B, Obermair A, Windbichler G, Petru E,
Mayerhofer S, Czerwenka K, Leodolter S, Kainz C, Mayerhofer K. Prognostic
parameters in endometrial stromal sarcoma: a clinicopathologic study in 31
patients. Gynecol Oncol. 2001;81:160-165.
6. Gadducci A, Sartori E, Landoni F, et al. Endometrial stromal sarcoma:
analysis of treatment failures and survival. Gynecol Oncol. 1996;63:247-253.
7. Berchuck A, Rubin SC, Hoskins WJ, et al. Treatment of endometrial
stromal tumors. Gynecol Oncol. 1990;36:60-65.
8. Shah JP, Bryant CS, Kumar S, et al. Lymphadenectomy and ovarian
preservation in low-grade endometrial stromal sarcoma. Obstet Gynecol.
2008;112:1102-1108.
9. Dos Santos LA, Garg K, Diaz JP, et al. Incidence of lymph node and
adnexal metastasis in endometrial stromal sarcoma. Gynecol Oncol. 2011;
121:319-322.
10. Barney B, Tward JD, Skidmore T, et al. Does radiotherapy or lymphadenectomy
improve survival in endometrial stromal sarcoma? Int J Gynecol
Cancer. 2009;19:1232-1238.
11. Maluf FC, Sabbatini P, Schwartz L, et al. Endometrial stromal sarcoma:
objective response to letrozole. Gynecol Oncol. 2001;82:384-388.
12. Chu MC, Mor G, Lim C, et al. Low-grade endometrial stromal sarcoma:
hormonal aspects. Gynecol Oncol. 2003;90:170-176.
13. Verschraegen CF, Vasuratna A, Edwards C, et al. Clinicopathologic
analysis of mullerian adenosarcoma: The M. D. Anderson Cancer Center
experience. Oncol Rep. 1998;5:939-944.
14. Abeler VM, Røyne O, Thoresen S, et al. Uterine sarcomas in Norway. A
histopathological and prognostic survey of a total population from 1970 to
2000 including 419 patients. Histopathology. 2009;54:355-364.
15. Soslow RA, Ali A, Oliva E. Mullerian adenosarcomas: an immunophenotypic
analysis of 35 cases. Am J Surg Pathol. 2008;32:1013-1021.
16. Veras E, Zivanovic O, Jacks L, et al. “Low-grade leiomyosarcoma” and
late-recurring smooth muscle tumors of the uterus: a heterogenous collection
of frequently misdiagnosed tumors associated with an overall favorable
prognosis relative to conventional uterine leiomyosarcomas. Am J Surg
Pathol. 2011;35:1626-1637.
17. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth
muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol.
1994;18:535-558.
18. Chen L, Yang B. Immunohistochemical analysis of p16, p53, and Ki-67
expression in uterine smooth muscle tumors. Int J Gynecol Pathol. 2008;27:
326-332.
19. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in
early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer.
1993;71:1702-1709.
20. Nordal RR, Kristense GB, Kaern J, et al. The prognostic significance of
stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma.
Acta Oncol. 1995;34:797-802.
21. Reed NS, Mangioni C, Malmström H, et al. Phase III randomised study
to evaluate the role of adjuvant pelvic radiotherapy in the treatment of
uterine sarcomas stages I and II: an European Organisation for Research and
Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).
Eur J Cancer. 2008;44:808-818
22. Zivanovic O, Leitao MM, Iasonos A, et al. Stage-specific outcomes of
patients with uterine leiomyosarcoma: a comparison of the international
Federation of gynecology and obstetrics and american joint committee on
cancer staging systems. J Clin Oncol. 2009;27:2066-2072.
23. Zivanovic O, Jacks LM, Iasonos A, et al. A nomogram to predict
postresection 5-year overall survival for patients with uterine leiomyosarcoma.
Cancer. 2012;118:660-669.
24. Giuntoli RL, Metzinger DS, DiMarco CS, et al. Retrospective review of
208 patients with leiomyosarcoma of the uterus: Prognostic indicators,
360
REFERENCES
MARTEE L. HENSLEY
surgical management, and adjuvant therapy. Gynecol Oncol. 2003;89:460-
469.
25. Hornback NB, Omura G, Major FJ. Observations on the use of adjuvant
radiation therapy in patients with stage I and II uterine sarcoma. Int J
Radiat Oncol Biol Phys. 1986;12:2127-2130.
26. Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of
adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group
Study. J Clin Oncol. 1985;3:1240-1245.
27. Hensley ML, Wathen K, Maki RG, et al. 3-year follow-up of SARC 005:
adjuvant treatment of high risk primary uterine leiomyosarcoma with gemcitabine/docetaxel
(GT) followed by doxorubicin (D). Connective Tissue Oncology
Society, Abstract ID: 1130375, 2011.
28. Leitao MM, Brennan MF, Hensley M, et al. Surgical resection of
pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecol
Oncol. 2002;87:287-294.
29. Clavero JM, Deschamps C, Cassivi SD, et al. Gynecologic cancers:
factors affecting survival after pulmonary metastasectomy. Ann Thorac Surg.
2006;81:2004-2007.
30. Sutton GP, Blessing JA, Barrett RJ, et al. Phase II trial of ifosfamide
and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group
study. Am J Obstet Gynecol. 1992;166:556-559.
31. Omura GA, Major FJ, Blessing JA, et al. A randomized study of
adriamycin with and without dimethyl triazenoimidazole carboxamide in
advanced uterine sarcomas. Cancer. 1983;52:626-632.
32. Look KY, Sandler A, Blessing JA, et al. Phase II trial of gemcitabine as
second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology
Group (GOG) study. Gynecol Oncol. 2004;92:644-647.
33. Talbot SM, Keohan ML, Hesdorffer M, et al. A phase II trial of
temozolomide in patients with unresectable or metastatic soft tissue sarcoma.
Cancer. 2003;98:1942-1946.
34. Boyar M, Hesdorffer M, Keohan M, et al. Phase II study of temozolomide
and thalidomide in patients with unresectable or metastatic leiomyosarcoma.
J Clin Oncol. 2005;23 (abstract 9029).
35. Ferriss JS, Atkins KA, Lachance JA, et al. Temozolomide in advanced
and recurrent uterine leiomyosarcoma and correlation with o6methylguanine
DNA methyltransferase expression: A case series. Int J
Gynecol Cancer. 2010;20:120-125.
36. Anderson S, Aghajanian C. Temozolomide in uterine leiomyosarcomas.
Gynecol Oncol. 2005;98:99-103.
37. Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743
(ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas:
multicenter phase II and pharmacokinetic study. J Clin Oncol. 2004;24:
5484-5492.
38. Delaloge S, Yovine A, Taamma A, et al. Ecteinascidin-743: a marinederived
compound in advanced, pretreated sarcoma patients-preliminary
evidence of activity. J Clin Oncol. 2001;19:1248-1255.
39. Monk BJ, Blessing JA, Street DG, et al. A phase II evaluation of
trabectedin in the treatment of advanced, persistent, or recurrent uterine
leiomyosarcoma: a gynecologic oncology group study. Gynecol Oncol. 2012;
124:48-52.
40. Hensley ML, Blessing JA, Mannel R, et al. Fixed-dose rate gemcitabine
plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a
Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008;109:329-334.
41. Hensley ML, Blessing JA, DeGeest K, et al. Fixed-dose rate gemcitabine
plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma:
a Gynecologic Oncology Group phase II study. Gynecol Oncol.
2008;109:323-328.
42. Sutton G, Blessing JA, Malfetano JH. Ifosfamide and doxorubicin in the
treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology
Group study. Gynecol Oncol. 1996;62:226-229.
43. O’Cearbhaill R, Zhou Q, Iasonos A, et al. Treatment of Advanced Uterine
Leiomyosarcoma with Aromatase Inhibitors. Gynecol Oncol. 2010;116:424-429.
44. D’Adamo DR, Anderson SE, Albritton K, et al. Phase II study of
doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.
J Clin Oncol. 2005;23:7135-7142.
45. Hensley ML, Sill MW, Scribner DR Jr, et al. Sunitinib malate in the
treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic
Oncology Group phase II study. Gynecol Oncol. 2009;115:460-465.
46. Maki RG, D’Adamo DR, Keohan ML, et al. Phase II study of sorafenib
in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27:
3133-3140.
47. Hensley ML. Principal Investigator. (GOG 0250, clinical trial identifier
NCT01012297).